{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:57Z","timestamp":1793041977794,"version":"4.5.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014996","name":"Health Commission of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008856","name":"Zhejiang Provincial Health Commission","doi-asserted-by":"publisher","award":["2023KY846"],"award-info":[{"award-number":["2023KY846"]}],"id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28098","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T05:24:28Z","timestamp":1710566668000},"page":"e28098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3362-9927","authenticated-orcid":false,"given":"Zhihao","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e28098_bib4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res."},{"key":"10.1016\/j.heliyon.2024.e28098_bib5","first-page":"425","article-title":"Chimeric antigen receptor T-cells: Properties, production, and quality control","volume":"45","author":"Ramesh","year":"2023","journal-title":"Int. J. Lit. Humanit."},{"key":"10.1016\/j.heliyon.2024.e28098_bib6","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib7","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1158\/0008-5472.CAN-10-2880","article-title":"Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e28098_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"Jun","year":"2018","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.heliyon.2024.e28098_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib10","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.heliyon.2024.e28098_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","article-title":"Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor","volume":"32","author":"Kochenderfer","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.heliyon.2024.e28098_bib14","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.7150\/jca.46308","article-title":"A brief review concerning Chimeric Antigen Receptors T cell therapy","volume":"11","author":"Li","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e28098_bib15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","article-title":"The Principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e28098_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"Gill","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2024.e28098_bib17","first-page":"260","article-title":"Focus on adoptive T cell transfer trials in melanoma","volume":"2010","author":"Hershkovitz","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib19","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1078-0432.CCR-06-1209","article-title":"Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration","volume":"13","author":"Bracci","year":"2007","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.heliyon.2024.e28098_bib20","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (Ido) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib21","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib22","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/hum.2022.183","article-title":"Efficacy and safety of Dual-targeting chimeric antigen receptor-T therapy for relapsed or refractory B cell lymphoid malignancies: a systematic review and meta-analysis","volume":"34","author":"Yu","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.heliyon.2024.e28098_bib24","doi-asserted-by":"crossref","first-page":"33961","DOI":"10.18632\/oncotarget.5582","article-title":"Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis","volume":"6","author":"Zhang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e28098_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745320","article-title":"Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-hodgkin lymphoma","volume":"12","author":"Caimi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib26","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.heliyon.2024.e28098_bib27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib29","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e28098_bib31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor T cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib33","first-page":"1245","article-title":"Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20\/CD19-specific chimeric antigen receptor redirected T cells in humans, Biology of blood and marrow transplantation","volume":"16","author":"Jensen","year":"2010","journal-title":"journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/j.heliyon.2024.e28098_bib34","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.heliyon.2024.e28098_bib35","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","article-title":"Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib37","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s11912-022-01330-z","article-title":"Supportive care for patients with lymphoma undergoing CAR-T-cell therapy: the advanced practice provider's perspective","volume":"24","author":"Granroth","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.heliyon.2024.e28098_bib38","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.heliyon.2024.e28098_bib39","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.heliyon.2024.e28098_bib40","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.heliyon.2024.e28098_bib41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma, molecular therapy","volume":"25","author":"Locke","year":"2017","journal-title":"the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.htct.2021.09.001","article-title":"Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. I: structuring centers for the multidisciplinary clinical administration and management of CAR-T cell therapy patients","volume":"43","author":"Cl\u00e9","year":"2021","journal-title":"Hematology, transfusion and cell therapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bmt.2013.152","article-title":"Hematopoietic SCT with cryopreserved grafts: adverse reactions after transplantation and cryoprotectant removal before infusion","volume":"49","author":"Shu","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.heliyon.2024.e28098_bib44","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jcyt.2019.07.004","article-title":"Preservation of cell-based immunotherapies for clinical trials","volume":"21","author":"Li","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib45","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib46","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib47","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/vox.12755","article-title":"Evaluation of DMSO dextrose as a suitable alternative for DMSO dextran in cord blood cryopreservation","volume":"114","author":"Raffo","year":"2019","journal-title":"Vox Sang."},{"key":"10.1016\/j.heliyon.2024.e28098_bib48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jcyt.2020.12.008","article-title":"Comparative analysis of cell therapy infusion workflows at clinical sites","volume":"23","author":"Joules","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib49","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"37","author":"Rioufol","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e28098_bib50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cryobiol.2009.12.001","article-title":"A biologist's view of the relevance of thermodynamics and physical chemistry to cryobiology","volume":"60","author":"Mazur","year":"2010","journal-title":"Cryobiology"},{"key":"10.1016\/j.heliyon.2024.e28098_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240310","article-title":"Automated dry thawing of cryopreserved haematopoietic cells is not adversely influenced by cryostorage time, patient age or gender","volume":"15","author":"Kilbride","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e28098_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000497289","article-title":"Technical considerations in the freezing, low-temperature storage and thawing of stem cells for cellular therapies","volume":"46","author":"Hunt","year":"2019","journal-title":"Transfus. Med. Hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie"},{"key":"10.1016\/j.heliyon.2024.e28098_bib53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2020006770","article-title":"Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies","volume":"137","author":"Gauthier","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib54","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib56","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10637-023-01344-9","article-title":"RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines","volume":"41","author":"Shang","year":"2023","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.heliyon.2024.e28098_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtct.2023.06.019","article-title":"Chimeric antigen receptor T cells as salvage therapy for post-chimeric antigen receptor T cell failure","volume":"29","author":"Holland","year":"2023","journal-title":"Transplantation and cellular therapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006596","article-title":"CAR T-cell detection scoping review: an essential biomarker in critical need of standardization","volume":"11","author":"Turicek","year":"2023","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.heliyon.2024.e28098_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.877477","article-title":"EASIX and severe endothelial complications after CD19-directed CAR-T cell therapy-A cohort study","volume":"13","author":"Korell","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib61","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.heliyon.2024.e28098_bib62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib63","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.heliyon.2024.e28098_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Current hematologic malignancy reports"},{"key":"10.1016\/j.heliyon.2024.e28098_bib65","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplantation and cellular therapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib66","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e28098_bib67","first-page":"625","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, biology of blood and marrow transplantation","volume":"25","author":"Lee","year":"2019","journal-title":"journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/j.heliyon.2024.e28098_bib68","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib70","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2024.e28098_bib71","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib72","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib73","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.heliyon.2024.e28098_bib74","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib75","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood advances"},{"key":"10.1016\/j.heliyon.2024.e28098_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e28098_bib77","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood advances"},{"key":"10.1016\/j.heliyon.2024.e28098_bib78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00280-002-0556-x","article-title":"Acute tumor lysis syndrome in solid tumors--a case report and review of the literature","volume":"51","author":"Baeksgaard","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib79","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3892\/ol.2014.2394","article-title":"Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome","volume":"8","author":"Takai","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.heliyon.2024.e28098_bib80","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1053\/j.ackd.2021.09.007","article-title":"Tumor lysis syndrome","volume":"28","author":"Barbar","year":"2021","journal-title":"Adv. Chron. Kidney Dis."},{"key":"10.1016\/j.heliyon.2024.e28098_bib81","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00134-019-05768-x","article-title":"Understanding tumor lysis syndrome","volume":"45","author":"Zafrani","year":"2019","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib82","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib83","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther. : the journal of the American Society of Gene Therapy"},{"key":"10.1016\/j.heliyon.2024.e28098_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e28098_bib85","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2024.e28098_bib86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13046-022-02540-w","article-title":"Dose fractionation of CAR-T cells. A systematic review of clinical outcomes","volume":"42","author":"Frigault","year":"2023","journal-title":"J. Exp. Clin. Cancer Res. : CR"},{"key":"10.1016\/j.heliyon.2024.e28098_bib87","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e28098_bib88","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402404129X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402404129X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:23:33Z","timestamp":1784208213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402404129X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":85,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S240584402404129X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28098","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28098"}}